Krouzon Pharmaceuticals
- Company typePrivate
- Founded2016
- HeadquartersNew Haven, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Krouzon Pharmaceuticals firmographics
Firmographics- Name
- Krouzon Pharmaceuticals
- Legal name
- Krouzon Pharmaceuticals, Inc.
- Website
- https://krouzon.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Krouzon Pharmaceuticals industry classification
Industry- Product category
- Rare Pediatric Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Krouzon Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Krouzon Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development and Commercialization: Pre-revenue biotech company developing pharmacological treatments for rare pediatric diseases. Revenue will be generated through drug commercialization upon regulatory approval, likely via prescription model for orphan/rare disease therapeutics.
Go-to-market motion1 record
Marketing channels3 records
Krouzon Pharmaceuticals product offering
Product offeringCore offering
Krouzon Pharmaceuticals is developing pharmacological therapeutics for children born with FGFR2-related Syndromic Craniosynostosis syndromes — Pfeiffer, Apert, and Crouzon syndromes. The drug development program focuses on creating disease-modifying treatments that target the root cause of FGFR2 mutations, aiming to restore normal child development and eliminate the need for lifelong invasive surgeries that constitute current standard of care.
Product overview
Krouzon Pharmaceuticals is developing a pipeline of pharmacological therapeutics for pediatric rare diseases, specifically targeting FGFR2-related Syndromic Craniosynostosis conditions including Pfeiffer syndrome, Apert syndrome, and Crouzon syndrome. The company's drug development program focuses on creating disease-modifying treatments to restore normal child development without the need for lifelong surgeries. These three therapeutic candidates represent Krouzon's core product portfolio in pediatric rare disease therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- Pfeiffer Syndrome Therapeutic Pharmacological therapeutic candidate targeting Pfeiffer syndrome, one of the most common FGFR2-related Syndromic Craniosynostosis conditions; designed to address the root cause of FGFR2 mutations and restore normal child development without lifelong surgeries.
- Apert Syndrome Therapeutic Pharmacological therapeutic candidate targeting Apert syndrome, an FGFR2-related Syndromic Craniosynostosis condition; part of Krouzon's drug development program focused on disease-modifying treatments for rare pediatric genetic disorders.
- Crouzon Syndrome Therapeutic Pharmacological therapeutic candidate targeting Crouzon syndrome, a FGFR2-related Syndromic Craniosynostosis condition; supported by the world's first disease model for Crouzon syndrome created by Krouzon's founder, enabling discovery of treatment methods.
Companies that use Krouzon Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Krouzon Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Krouzon Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ABCT (Accelerator for Biosciences in Connecticut)coreSelected as one of 12 High-Potential Life Science Startups for Connecticut's Accelerator Program. The 6.5-month program features business education to develop fundable business plans, professional network access, entrepreneur coaching, active business professional access, and investor pitch preparation.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Krouzon Pharmaceuticals competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Krouzon Pharmaceuticals social profiles
Digital presenceKrouzon Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Krouzon Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
Krouzon Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Krouzon Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Krouzon Pharmaceuticals
What does Krouzon Pharmaceuticals do?
Krouzon Pharmaceuticals is developing pharmacological therapeutics for children born with FGFR2-related Syndromic Craniosynostosis syndromes — Pfeiffer, Apert, and Crouzon syndromes. The drug development program focuses on creating disease-modifying treatments that target the root cause of FGFR2 mutations, aiming to restore normal child development and eliminate the need for lifelong invasive surgeries that constitute current standard of care.
Is Krouzon Pharmaceuticals a public or private company?
Krouzon Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Krouzon Pharmaceuticals founded?
Krouzon Pharmaceuticals was founded in 2016. It employs 1 to 10 people.
Where is Krouzon Pharmaceuticals based?
Krouzon Pharmaceuticals is headquartered in New Haven, United States, in the North America region.
How does Krouzon Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Does Krouzon Pharmaceuticals have an API?
No public API is recorded for Krouzon Pharmaceuticals.
What industry is Krouzon Pharmaceuticals in?
Krouzon Pharmaceuticals's product category is Rare Pediatric Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.